SCHEDULE: Cevian Capital Boosts Smith & Nephew Stake

Cevian Capital II GP Ltd has increased its beneficial ownership of Smith & Nephew plc shares to 10.71%, acquiring over 91 million shares for approximately $1.29 billion.

Summary

• Cevian Capital II GP Ltd, through its Cevian Funds, has acquired an additional 91,462,095 ordinary shares of Smith & Nephew plc.
• The total consideration for these shares, including brokerage commissions, amounts to approximately USD $1,286,286,786.
• These purchases were funded from the general working capital of the Cevian Funds and were conducted in British Pounds, with a conversion rate of USD $1.36225 per GBP 1.00 used for reporting.
• As of April 30, 2026, Cevian Capital II GP Ltd beneficially owns 10.71% of Smith & Nephew plc's outstanding ordinary shares, based on 854,049,145 shares outstanding.
• The filing is an amendment (Amendment No. 5) to a previously filed Schedule 13D, updating information on beneficial ownership and transactions.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development due to the significant investment by a known activist investor, suggesting potential for strategic improvements, though it also introduces potential for disruption.

Positives

• Cevian Capital II GP Ltd has significantly increased its investment in Smith & Nephew plc, indicating strong conviction in the company's future prospects.
• The acquisition of a substantial stake (10.71%) suggests potential for active engagement and influence in the company's strategic direction.
• The transactions detailed in Schedule C show consistent purchasing activity over a period, demonstrating a sustained commitment to acquiring shares.

Negatives

• The substantial increase in stake by a single activist investor could signal underlying concerns about the company's current performance or strategic direction, prompting increased scrutiny.
• The aggregate purchase price of over $1.28 billion represents a significant capital deployment, the success of which is contingent on future company performance.

Risks

• Increased scrutiny from regulatory bodies and the market due to the significant ownership stake.
• Potential for activist investor pressure to influence company strategy, which may not align with all stakeholders' interests.
• Market volatility impacting the value of the acquired shares.

Future Outlook

The filing itself does not contain forward-looking statements or guidance from Smith & Nephew plc. It is a disclosure of beneficial ownership by Cevian Capital II GP Ltd.

Industry Context

StockSavvy.ai notes that Cevian Capital's increased stake in Smith & Nephew plc aligns with a broader trend of activist investors targeting established companies in the healthcare and medical device sectors, seeking to unlock shareholder value through operational improvements or strategic realignments.

Stakeholder Impact

• Shareholders: Potential for increased share value if activist pressure leads to improved company performance or strategic changes; also potential for short-term volatility.
• Management and Board of Directors: Increased scrutiny and potential pressure to implement changes advocated by Cevian Capital.
• Employees: Uncertainty regarding future strategic direction and potential restructuring.
• Creditors and Suppliers: Stability of the company's financial health remains a key factor, with potential for changes in strategic focus.

Next Steps

• Continued monitoring of Cevian Capital's activities and potential influence on Smith & Nephew plc's strategy.
• Further SEC filings may be required to disclose any subsequent changes in beneficial ownership or significant corporate actions.

Key Dates

Recommendation

The filing indicates a significant increase in stake by an activist investor, which could lead to positive strategic changes but also introduces uncertainty. A 'hold' recommendation is appropriate pending further clarity on Cevian Capital's specific objectives and the company's response.

Keywords

Smith & Nephew plc, Cevian Capital, Schedule 13D, Beneficial Ownership, Ordinary Shares, Activist Investor, SEC Filing, Investment, Healthcare, Medical Devices